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Reduced Necrosis and Content 
of Apoptotic M1 Macrophages in 
Advanced Atherosclerotic Plaques 
of Mice With Macrophage-Specific 
Loss of Trpc3
Sumeet Solanki1, Prabhatchandra R. Dube1, Lutz Birnbaumer2,3 & Guillermo Vazquez1
In previous work we reported that ApoeKO mice transplanted with bone marrow cells deficient in 
the Transient Receptor Potential Canonical 3 (TRPC3) channel have reduced necrosis and number 
of apoptotic macrophages in advanced atherosclerotic plaques. Also, in vitro studies with polarized 
macrophages derived from mice with macrophage-specific loss of TRPC3 showed that M1, but not 
M2 macrophages, deficient in Trpc3 are less susceptible to ER stress-induced apoptosis than Trpc3 
expressing cells. The questions remained (a) whether the plaque phenotype in transplanted mice 
resulted from a genuine effect of Trpc3 on macrophages, and (b) whether the reduced necrosis and 
macrophage apoptosis in plaques of these mice was a manifestation of the selective effect of TRPC3 on 
apoptosis of M1 macrophages previously observed in vitro. Here, we addressed these questions using 
Ldlr knockout (Ldlr−/−) mice with macrophage-specific loss of Trpc3 (MacTrpc3−/−/Ldlr−/− → Ldlr−/−). 
Compared to controls, we observed decreased plaque necrosis and number of apoptotic macrophages in 
MacTrpc3−/−/Ldlr−/− → Ldlr−/− mice. Immunohistochemical analysis revealed a reduction in apoptotic 
M1, but not apoptotic M2 macrophages. These findings confirm an effect of TRPC3 on plaque necrosis 
and support the notion that this is likely a reflection of the reduced susceptibility of Trpc3-deficient M1 
macrophages to apoptosis.
Atherosclerosis is the main cause of coronary heart disease, a leading determinant of morbidity and mortality in 
the United States1. Clinical manifestations of atherosclerosis include ischemic symptoms due to plaques causing 
critical stenosis or thromboembolic events that often follow the rupture of vulnerable plaques2,3. The process that 
mediates atherosclerotic plaque formation and growth involves an intricate interaction between smooth muscle 
cells, endothelial cells, monocyte-derived macrophages, and a myriad of cytokines and inflammatory mediators 
that lodge in the plaque4. Among these, macrophages are recognized as central players throughout all stages of the 
disease. Macrophage apoptosis is one of the most influential events in shaping plaque features and determining 
their progression. In advanced plaques in particular, where the removal of apoptotic macrophages –efferocytosis- 
is impaired, the accumulation of apoptotic bodies favors the growth of the necrotic core, mostly through second-
ary necrosis, and adds to the factors that contribute to plaque instability5,6. An often ignored aspect is the fact that 
the macrophage population in the plaque is composed of phenotypically and functionally distinct subsets. The 
M1 or inflammatory, and M2 or anti-inflammatory types dominate in atherosclerosis7–9. The relative abundance 
of M1 and M2 macrophages varies with lesion stage, generally increasing as lesion progresses. Yet, both types 
co-exist throughout lesion development, intermediate phenotypes seem to exist and phenotype inter-conversion 
can occur8,10.
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Transient Receptor Potential Canonical 3 (TRPC3) is a calcium-permeable channel that belongs to the 
TRPC family of non-selective cation channels11. Under physiological conditions TRPC3 is activated by 
receptor-dependent activation of phosphoinositide-specific phospholipases and also exhibits significant consti-
tutive function11,12. The participation of TRPC3 in molecular and cellular processes associated to the pathophys-
iology of cardiovascular disease is well documented13–15. Our laboratory was the first in examining the functions 
of TRPC3 in macrophage biology and its implications in atherosclerosis4. One of these studies showed that loss 
of TRPC3 function impairs the survival of naïve bone marrow-derived macrophages16, leading to the speculation 
that in the setting of atherosclerosis, deletion of macrophage Trpc3 would lead to accumulation of apoptotic cells 
and increased plaque necrosis. Contrary to this prediction, our recent observations in Apoe knockout mice trans-
planted with bone marrow from Trpc3−/−/Apoe−/− or Trpc3+/+/Apoe−/− animals, showed that some of the typical 
features of advanced plaques were actually alleviated by bone marrow deletion of Trpc317. Compared to control 
animals, advanced lesions in the aortic root of mice with bone marrow deletion of Trpc3 showed reduction in 
necrosis and in the content of apoptotic macrophages, with no changes in lesion size or cellularity17. This was 
interpreted as potentially reflecting an effect of TRPC3 on polarized macrophages, which are abundant in plaques, 
and different from the observed in vitro effect on naïve macrophages. In line with this interpretation, M1 but not 
M2 macrophages prepared from mice with Trpc3 deficient bone marrow or from mice with macrophage-specific 
loss of TRPC3, were less sensitive to endoplasmic reticulum (ER) stress-induced apoptosis than TRPC3 express-
ing M1 cells17,18. Among the immune cells found in murine atherosclerotic plaques, lymphocytes, neutrophils and 
dendritic cells do not express TRPC319–23. Thus, despite the fact that the bone marrow cells used in the studies 
described above were derived from mice with global deletion of Trpc3, it was reasonable to conclude that the 
observed plaque phenotype was presumably due to the impact of Trpc3 deficiency on macrophage apoptosis17. 
However, two important questions remained unanswered. First, whether Trpc3 deletion in bone marrow cells 
other than myeloid precursors – v.g., bone marrow-derived progenitors for endothelial and smooth muscle cells- 
could have contributed to the plaque phenotype in mice with bone marrow deletion of Trpc3. Second, whether 
the reduced necrosis and macrophage apoptosis observed in advanced plaques of the transplanted animals was to 
some extent a consequence of the selective effect of TRPC3 on apoptosis of M1 macrophages previously observed 
in vitro17,18.
To address these important questions, in the present work we used the low density lipoprotein recep-
tor knockout (Ldlr−/−) mouse model of atherosclerosis transplanted with bone marrow from mice with 
macrophage-specific loss of TRPC3 (MacTrpc3−/−/Ldlr−/−) or control Ldlr−/− animals and examined the 
characteristics of advanced atherosclerotic lesions (14 weeks on high fat diet). In agreement with previous 
findings, we observed a marked decrease in necrosis and number of apoptotic macrophages in Ldlr−/− mice 
with macrophage-specific loss of TRPC3 compared to controls. Notably, immunohistochemical examination 
of advanced plaques revealed a reduction in apoptotic M1 macrophages, but not in apoptotic M2 cells. These 
observations support the previous in vitro findings on polarized macrophages, and indicate that in advanced 
atherosclerotic plaques the beneficial impact of macrophage-specific deletion of Trpc3 likely reflects the reduced 
susceptibility of Trpc3-deficient M1 macrophages to apoptosis in the plaque setting.
Results
In this study we directly examined the impact of macrophage-specific deletion of Trpc3 on the characteristics 
of advanced atherosclerotic lesions in Ldlr−/− mice fed a conventional high fat diet. We undertook a bone mar-
row transplantation approach in which Ldlr−/− mice were used as recipients of bone marrow from mice with 
macrophage-specific loss of TRPC3 (on Ldlr−/− background, MacTrpc3−/−/Ldlr−/−). Six week-old female Ldlr−/− 
mice were lethally irradiated and transplanted with bone marrow from Ldlr−/− (control group: Ldlr−/− → Ldlr−/−) 
or from MacTrpc3−/−/Ldlr−/− mice (study group: MacTrpc3−/−/Ldlr−/− → Ldlr−/−) following protocols previ-
ously described17,24. Conversion to the donor’s phenotype was confirmed four weeks after transplantation by 
PCR on gDNA from peripheral blood (Supplemental Figure S1). Next, all mice were placed on a high fat diet 
(HFD; TD.88137, Harlan Teklad) for 14 weeks. We previously showed that bone marrow-transplanted Ldlr−/− 
mice subjected to this regimen develop advanced atherosclerotic lesions24. At the end of the diet period, bone 
marrow-derived macrophages were prepared from both groups of mice and the levels of Trpc3 mRNA were 
examined by qRT-PCR. As expected, there was a marked decrease in TRPC3 expression in macrophages derived 
from mice with macrophage-specific loss of TRPC3, but not in control cells (Supplemental Figure S2).
At sacrifice, body weight, total cholesterol and triglycerides were recorded. As shown in Table S1, these param-
eters were comparable between both groups of mice. Cholesterol distribution in lipoprotein fractions was also 
similar between both groups (not shown). To examine the impact of macrophage-specific loss of TRPC3 on typi-
cal features of advanced atherosclerotic lesions we performed histological analysis of aortic root sections as in17,25. 
Based on the morphometric evaluation of hematoxylin-eosin stained sections, we found no significant differences 
in total plaque area between the control and study groups [444,777 ± 63,171 μ m2 (n = 10) vs. 392,003 ± 37,823 μ m2 
(n = 11), for Ldlr−/− → Ldlr−/− and MacTrpc3−/−/Ldlr−/− → Ldlr−/− mice, respectively, p = 0.47; Fig. 1]. Neutral 
lipid content, assessed by Oil Red O (ORO) staining, was not different [365,752 ± 44,742 μ m2 (n = 10) vs. 
377,134 ± 28,600 μ m2 (n = 11), for Ldlr−/− → Ldlr−/− and MacTrpc3−/−/Ldlr−/− → Ldlr−/− mice, respectively, 
p = 0.82; Supplemental Figure S3]. The macrophage content of aortic root plaques was also similar between 
groups [CD68-positive area normalized by total lesion area: 64.09 ± 5.18% (n = 9) vs. 68.67 ± 4.49% (n = 11), for 
Ldlr−/− → Ldlr−/− and MacTrpc3−/−/Ldlr−/− → Ldlr−/− mice, respectively, p = 0.51; Fig. 2].
In most advanced plaques that develop after 14 weeks of HFD feeding, the presence of areas of necrosis is 
clearly noticeable. When we compared the necrosis content of plaques between MacTrpc3−/−/Ldlr−/− → Ldlr−/− 
and Ldlr−/− → Ldlr−/− mice, we observed a significant reduction in percent necrotic area in plaques from mice 
with macrophage-specific loss of TRPC3 compared to control animals [respectively, 23.12 ± 2.07% (n = 11) 
vs. 39.63 ± 5.93% (n = 10), p = 0.01); Fig. 3]. Cap thickness was similar between both groups [14.5 ± 1.2 vs. 
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Figure 1. Aortic root sections from Ldlr−/− → Ldlr−/− or MacTrpc3−/−/Ldlr−/− → Ldlr−/− mice that were 
maintained on a high fat diet for 14 weeks were stained with hematoxylin-eosin to evaluate atherosclerotic 
plaque area. Quantitations of mean stained areas are shown (mean ± SEM). Ldlr−/− → Ldlr−/− (n = 10), 
MacTrpc3−/−/Ldlr−/− → Ldlr−/− (n = 11). Total magnification: 50x .
Figure 2. Aortic root sections from Ldlr−/− → Ldlr−/− or MacTrpc3−/−/Ldlr−/− → Ldlr−/− mice that were 
maintained on a high fat diet for 14 weeks, were stained with anti-CD68 antibody to evaluate macrophage 
content. Shown are representative sections of CD68 staining and corresponding quantitation of the stained 
areas (mean ± SEM) from Ldlr−/− → Ldlr−/− (n = 9) or MacTrpc3−/−/Ldlr−/− → Ldlr−/− (11) mice. Total 
magnification: 50x .
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14.3 ± 0.9 μ m, n = 9, p = 0.907]. Based on Movat’s pentachrome staining, the collagen content in aortic root sec-
tions from MacTrpc3−/−/Ldlr−/− → Ldlr−/− was not different from that in Ldlr−/− → Ldlr−/− mice [respectively, 
7.78 ± 0.92% (n = 8) vs. 7.06 ± 0.97% (n = 9), p = 0.602; Supplemental Figure S4]. In addition, immunostaining 
for α -smooth muscle actin did not show differences in smooth muscle content in the aortic root sections between 
the two groups of animals [9.60 ± 2.0% (n = 6) vs. 8.8 ± 1.6% (n = 6), for Ldlr−/− → Ldlr−/− and MacTrpc3−/−/
Ldlr−/− → Ldlr−/− mice, respectively, p = 0.807; Supplemental Figure S4].
Macrophage apoptosis is a key determinant of necrosis in advanced plaques5. Using a modified in situ TUNEL 
technique (described previously in refs 17,24) we examined whether macrophage-specific loss of TRPC3 had any 
effect in the accumulation of apoptotic macrophages in advanced lesions. Simultaneous staining of aortic root 
sections for TUNEL and CD68 revealed that plaques from MacTrpc3−/−/Ldlr−/− → Ldlr−/− mice had a signifi-
cantly reduced number of apoptotic macrophages (CD68+TUNEL+ cells) compared to controls [25.43 ± 5 cells/
mm2 (n = 6) vs. 8.40 ± 1 cells/mm2 (n = 6), for Ldlr−/− → Ldlr−/− and MacTrpc3−/−/Ldlr−/− → Ldlr−/− mice, 
respectively, p = 0.008; Supplemental Figure S5].
In a recent study we showed that, in vitro, macrophage-specific loss of TRPC3 selectively reduces the sus-
ceptibility of M1, but not that of M2 macrophages, to ER stress-induced apoptosis18. Therefore, to gather insight 
whether this was also the case for polarized macrophages in the plaque setting, we evaluated the number of 
TUNEL-positive cells that overlapped with iNOS+CD68+ (M1 macrophages) or with CD206+CD68+ (M2 mac-
rophages) cells. As shown in Fig. 4, immunoreactivity for M1 and M2 macrophages was clearly noticeable in 
plaques from both groups of mice. Interestingly, the comparison of sections co-immunostained for M1 mac-
rophages (iNOS+CD68+) with the corresponding TUNEL-stained consecutive sections, showed that plaques 
from MacTrpc3−/−/Ldlr−/− → Ldlr−/− mice had a significantly reduced number of apoptotic cells overlapping 
with M1 macrophages than lesions from Ldlr−/− → Ldlr−/− mice [respectively, 3.9 ± 0.3 (n = 12) vs. 5.8 ± 0.3 
(n = 9), TUNEL+ cells overlapping with iNOS+CD68+ cells, per total M1 cells, p = 0.02, Fig. 4A]. Applying 
the same analysis we did not observe significant differences in the number of apoptotic cells overlapping with 
CD206+CD68+ cells (M2 macrophages) [6.13 ± 1.26 (n = 8) vs. 7.07 ± 2.53 (n = 6), TUNEL+ cells overlapping 
with CD206+CD68+ cells per total M2 cells, for MacTrpc3−/−/Ldlr−/− → Ldlr−/− vs. Ldlr−/− → Ldlr−/− mice, 
respectively, p = 0.77, Fig. 4B]. To further characterize the phenotype of iNOS+ or CD206+ cells within CD68 
immunoreactive areas, we isolated iNOS+ or CD206+ cells co-localizing with CD68+ (macrophages) cells from 
aortic root plaques of Ldlr−/− → Ldlr−/− and MacTrpc3−/−/Ldlr−/− → Ldlr−/− mice using laser capture microdis-
section (LCM), and evaluated the expression level of additional M1 and M2 markers (Supplemental Figure S6). 
As expected, iNOS, Arg2 and TNFα were highly expressed in LCM-captured iNOS+ cells, compared to the M2 
markers Arg1, CD206 and Ym1. The opposite pattern was observed in LCM-captured CD206+ cells. There were 
no differences in the expression level or distribution of M1 and M2 markers between macrophages isolated from 
Ldlr−/− → Ldlr−/− and MacTrpc3−/−/Ldlr−/− → Ldlr−/− mice. The almost undetectable expression of Trpc3 in 
Figure 3. Aortic root sections from Ldlr−/− → Ldlr−/− or MacTrpc3−/−/Ldlr−/− → Ldlr−/− mice fed a 
high fat diet during 14 weeks were stained with hematoxylin and eosin to evaluate necrosis. Shown are 
representative sections with areas of necrosis delimited by green traces. Quantification of necrotic areas is 
provided as the percent of necrosis within the total lesion area (mean ± SEM). Total magnification: 50x .
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Figure 4. Aortic root sections from Ldlr−/− → Ldlr−/− or MacTrpc3−/−/Ldlr−/− → Ldlr−/− mice that were 
maintained on high fat diet for 14 weeks were processed for (A) co-immunostaining for iNOS (M1 marker, 
red) and CD68 (macrophage marker, green), and the corresponding consecutive section processed for in situ 
TUNEL to detect apoptotic cells. Nuclei were stained with DAPI. (B) co-immunostaining for mannose receptor 
(CD206, M2 marker, red) and CD68 (green), and the corresponding consecutive section processed for in situ 
TUNEL. The arrows point to TUNEL+ cells; dotted line areas delineate iNOS+CD68+ or CD206+CD68+ cells. 
Typical immunoreactive areas (white-dotted box in full image) are shown at higher magnification in the insets. 
Total magnification: 100x .
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LCM-captured macrophages from plaques of MacTrpc3−/−/Ldlr−/− → Ldlr−/− mice confirms deletion of mac-
rophage Trpc3 in the lesion setting.
To examine whether the effect of macrophage-deficiency of Trpc3 on apoptosis of M1 macrophages had 
an impact on their relative abundance in lesions from MacTrpc3−/−/Ldlr−/− → Ldlr−/− mice compared to 
Ldlr−/− → Ldlr−/− animals, we measured the extent of iNOS and CD206 immunoreactivity overlapping with 
CD68-positive areas, and compared the relative areas within and between groups. As shown in Fig. 5, there were 
no significant differences in the proportions of M1 or M2 macrophages between MacTrpc3−/−/Ldlr−/− → Ldlr−/− 
and Ldlr−/− → Ldlr−/− mice; accordingly, the M1/M2 ratios were not different between the two groups [M1/M2 
ratios: 1.43 ± 0.13 vs. 1.69 ± 0.09, for plaques from Ldlr−/− → Ldlr−/− and MacTrpc3−/−/Ldlr−/− → Ldlr−/− mice, 
respectively; n = 6, p = 0.117].
Discussion
The present study was aimed at examining the impact of macrophage-specific loss of TRPC3 on typical features 
of advanced atherosclerotic lesions in a mouse model of atherosclerosis. Two major findings were made. First, the 
Figure 5. Aortic root sections from Ldlr−/− → Ldlr−/− or MacTrpc3−/−/Ldlr−/− → Ldlr−/− mice that were 
maintained on high fat diet for 14 weeks, were immunostained for (A) CD68 (total macrophage content) or 
iNOS (M1 macrophages), (B) CD68 or CD206 (M2 macrophages), as indicated. Stainings for CD68 and iNOS 
or CD68 and CD206, were performed on consecutive sections. The quantitation (mean ± SEM) of stained 
areas for iNOS and CD206 were normalized by total CD68-positive area; n = 5, ns: not statistically significant 
difference. The dotted lines show representative iNOS+ or CD206+ areas that overlap with CD68+ areas. Total 
magnification: 50X .
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lack of macrophage TRPC3 was associated to an important reduction in plaque necrosis, compared to lesions in 
mice from the control group. Second, plaques in mice with macrophage-specific loss of TRPC3 had a significantly 
reduced number of apoptotic cells that co-localized with regions immunoreactive for M1 macrophages, in com-
parison to control animals. These findings are important not only in the general context of the effects of TRPC3 
in macrophage biology and atherosclerosis, but also in the light of our previous in vitro and in vivo studies on the 
specific roles of macrophage TRPC3 in atherorelevant processes.
In previous work using Apoe knockout mice transplanted with bone marrow from mice with global deficiency 
of Trpc3 we also found a reduction in necrosis and in the number of apoptotic macrophages in advanced stage 
atherosclerotic lesions17. Considering that mouse lymphocytes, neutrophils and dendritic cells do not express 
TRPC319–23, it was then concluded that the findings in ApoeKO mice were, presumably, the consequence of an 
effect of Trpc3 deficiency on plaque macrophages17. However, since the donor mice were global knockouts for 
Trpc3, this model gave rise to the question whether Trpc3 deletion in bone marrow cells other than myeloid 
precursors could have contributed to the observed plaque phenotype17. In this context, the present findings spe-
cifically address that question and provide a conclusive answer demonstrating that the loss of macrophage TRPC3 
is indeed associated to a reduction in necrosis and in macrophage apoptosis in plaques.
When we first examined the effect of TRPC3 on mechanisms of macrophage survival/apoptosis, we found 
that the loss of TRPC3 function resulted in increased apoptosis of naïve macrophages26. The prediction that this 
effect would result in accumulation of apoptotic macrophages in advanced plaques of mice with macrophage 
loss of TRPC3 is proven wrong by both the present findings and the previous observations in the ApoeKO bone 
marrow transplantation model17. Indeed, from these observations it was obvious that in the plaque setting the 
impact of Trpc3 deficiency on apoptosis of macrophages was quite different from what we found in vitro in 
naïve macrophages. Since M1 and M2 macrophages are the predominant types in atherosclerotic lesions27,28, 
we concluded that the in vivo findings in the ApoeKO transplantation model were likely reflecting a distinctive 
effect of TRPC3 on polarized macrophages17. This interpretation was strongly supported by our recent in vitro 
studies showing that M1, but not M2 macrophages prepared from mice with macrophage-specific loss of TRPC3 
have a significant reduction in their susceptibility to undergo apoptosis when subjected to chronic ER stress, a 
well-recognized mechanism that promotes macrophage death in the plaque setting17,18. The in vivo relevance of 
these in vitro observations is, to a great extent, supported by the findings in the present work. Indeed, the athero-
sclerotic plaques in mice with macrophage-specific loss of TRPC3 have, compared to control animals, a reduced 
number of apoptotic cells that co-localize with areas immunoreactive for iNOS and CD68, presumably indicative 
of reduced number of apoptotic M1 macrophages.
The reduction in plaque necrosis in mice with macrophage-specific loss of TRPC3 was not accompanied by 
changes in plaque size or lipid content, which were not different compared to control animals. This lack of corre-
lation between changes in necrotic core size and plaque burden is not uncommon, and is thought to be related to 
the fact that necrosis results from a complex interaction between macrophage apoptosis, clearance of apoptotic 
bodies, trafficking of macrophages and/or in situ proliferation, all of which do not necessarily parallel plaque 
growth29.
More unexpected however, was the lack of correlation between the reduction in number of apoptotic mac-
rophages and the plaque macrophage content in mice with macrophage-specific loss of TRPC3. Intuitively, in the 
advanced plaque setting where cell egress is impaired30,31, one would anticipate that reduced apoptosis should 
lead to accumulation of surviving cells and this, while delaying necrotic core growth, would result in increased 
plaque cellularity and size. Clearly, this was not the case in the MacTrpc3−/−/Ldlr−/− → Ldlr−/− mice. Of impor-
tance, efferocytosis in the plaque environment was not affected by macrophage-deficiency of Trpc3, since in situ 
efferocytosis, as assessed from the ratio of “free” vs. “macrophage-associated” apoptotic cells, was similar between 
plaques of Ldlr−/− → Ldlr−/− and MacTrpc3−/−/Ldlr−/− → Ldlr−/− mice (Supplemental Figure S7). Altogether, 
these findings suggest that some sort of relocation of surviving M1 cells may have occurred, which prevented 
their accumulation from causing changes in plaque volume. Interestingly, in a recent study aimed at analyzing the 
transcriptome of M1 macrophages, we found marked changes in expression levels of several genes linked to cell 
movement in Trpc3-deficient M1 macrophages compared to Trpc3-expressing cells, suggesting that alterations 
exist in motility pathways in Trpc3-deficient M1 macrophages32. This contention was supported by data from 
an in vitro migration assay showing that Trpc3-deficient M1 macrophages exhibit increased migratory response 
to CCL232. Additional studies are needed to specifically examine the effect of Trpc3 deficiency on the migration 
capability of M1 macrophages in vivo.
In humans, rupture of vulnerable plaques causes an important number of acute thromboembolic events3,33. 
Indeed, positive correlations have been found between the size of the necrotic core and the incidence of ruptured 
plaques, the area of necrosis often representing more than 25% of the total plaque area33. By analogy, one thus 
would anticipate that the reduction of 40% in necrosis content observed here in mice with macrophage-specific 
loss of TRPC3 should be significant in the context of plaque stability. However, with few exceptions, plaque rup-
ture is a controversial event in mice as there is no indication that fibrous cap rupture with luminal thrombosis 
truly occurs in these animals34. Also, the histomorphometric analysis in the present study was conducted in 
plaques of the aortic root, and there is no evidence of plaque disruptions occurring in this vascular bed site35–37. 
The brachiocephalic artery is a preferred site for plaque stability studies because plaque disruptions do occur 
and it models human pathology better than other anatomical locations in the mouse35,38. In the timeframe of our 
studies we did not find advanced plaques in the brachiocephalic artery, and thus longer periods of high fat feeding 
may be required to conduct lesion stability analysis at this vascular site. When that information becomes availa-
ble, the present observations will be of value to evaluate if and to what extent changes in surrogate parameters in 
the aortic root correlate with similar measures in the brachiocephalic artery.
Most desirable goals in the clinical management of atherosclerosis are to reduce the progression of plaques, 
stimulate their regression, and/or improve stability of vulnerable plaques. Macrophages are central players in all of 
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these processes. Yet, the potential applicability to human disease of strategies aimed at manipulating apoptosis – 
a major contributor to necrosis and plaque instability- or migration –key to plaque regression- of plaque mac-
rophages is still under debate. An often disregarded aspect is that macrophages in the plaque are phenotypically 
and functionally heterogenous. Acknowledging the distinctive impact of macrophage diversity on plaque devel-
opment and progression is important, as it may lead to definitions to design alternative therapeutic strategies. 
The identification of molecular elements that specifically contribute to atherorelevant functions of a particular 
macrophage type but not others remains an unmet goal. Filling this gap in knowledge may drive drug develop-
ment towards targeting detrimental events in a phenotype selective manner, while minimally interfering with 
the desirable types. For instance, in mouse models of plaque regression, successful reduction in plaque burden is 
often paralleled by enrichment in M2 macrophages39,40. It has been shown that ER stress favors differentiation of 
M2 macrophages, and suppression of ER stress shifts M2s towards an M1 phenotype41. Intuitively, this suggests 
that interventions aimed at targeting components of the unfolded protein response as a strategy to reduce ER 
stress-induced apoptosis with no discrimination of phenotypes, may favor M2-to-M1 conversion. This would 
have a predictable negative effect on necrosis and/or regression of advanced plaques. Thus, manipulating apop-
tosis of plaque macrophages in a phenotype selective manner is an attractive, alternative strategy to potentially 
improve stability and/or eventually favor regression of plaques. Molecular elements that contribute to these pro-
cesses in a phenotype selective manner have not been so far described. In this context, the present findings sup-
porting a selective effect of Trpc3 on apoptosis of M1 macrophages in the plaque setting, may represent a first step 
towards reaching that goal.
Materials and Methods
Experimental animals. All animal studies described in this work conform to the Guide for Care and Use 
of Laboratory Animals published by the NIH and have been approved by the University of Toledo Institutional 
Animal Care and Use Committee. Generation and characterization of LysMCre+/−/Trpc3lox/lox mice (for sim-
plicity, MacTrpc3−/−) was described in detail in ref. 18. MacTrpc3−/−/Ldlr−/− mice were generated by crossing 
MacTrpc3−/− (C57BL/6 background) with low density lipoprotein receptor knockout (“Ldlr−/−”, B6.129S7-
Ldlrtm1Her/J, Jackson Labs, ME) for 10 generations. All colonies were maintained in our animal facility (Division 
of Laboratory Animal Research, University of Toledo). Euthanasia was performed by intraperitoneal injection of 
sodium pentobarbital (150 mg/kg) added to an anti-coagulant (heparin, 10 Units/ml).
Preparation of bone marrow-derived macrophages. Culture of bone marrow-derived macrophages, 
in vitro differentiation to the M1 or M2 types and phenotypic marker profiling was performed as in ref. 18.
Bone marrow transplantation (BMT). This was conducted essentially as we described in ref. 17. 
Briefly, recipient mice (Ldlr−/− females, 6-week-old, C57BL/6 background) were irradiated (10 Gy, 3 min; 
137Cs-Gammacell 40 Exactor, Nordion Int. Inc.) and 4 hours later injected via tail vein with bone marrow cells 
(~5 × 106 cells) from Ldlr−/− or MacTrpc3−/−/Ldlr−/− mice. Preparation of bone marrow cells from donors is 
described in ref. 17. Conversion to the donor’s phenotype was confirmed four weeks after transplantation by PCR 
of genomic DNA from peripheral blood (Supplemental Figure S1). Recipients of bone marrow from Ldlr−/− mice 
exhibited the expected 380 bp amplicon (wild-type Trpc3), whereas recipients of bone marrow from mice with 
macrophage-specific loss of Trpc3 showed the 461 bp amplicon corresponding to the floxed Trpc3 gene. The 
primers used for Trpc3 were: F: GAT GGC TCA GCA GTT AAA AGC TCT GG; R: GAA GTC ACT TCA GAC 
AGT CCA AAT AT. PCR for LDLR was performed using the primers and conditions recommended by Jackson 
Labs (Jackson Labs, ME).
Determination of plasma cholesterol and triglycerides. After 12 h of fasting blood was collected by 
submandibular vein puncture. Total plasma cholesterol and triglycerides were determined using Cholesterol-E 
and L-Type Triglyceride-M (Wako Chemicals USA, Inc.) following manufacturer’s instructions.
Aortic root sectioning. Aortic root sections were prepared as described in ref. 42. Briefly, euthanized mice 
were perfused through the left ventricle with 4% paraformaldehyde followed by PBS. The heart was cut so that 
all three aortic valves were in the same geometric plane. The upper portion of the heart was embedded in O.C.T., 
frozen in the Peltier stage of the cryostat (Thermo Scientific R. Allan HM550 Cryostat) and processed for section-
ing. Sections (10 μ m) were collected onto Fisher Superfrost Plus-coated slides, starting from where aorta exits the 
ventricle and moving towards the aortic sinus over ~650–700 μ m. Sections were collected following the scheme 
that we used in ref. 42, which is based on that described by Daugherty and Whitman43. Essentially, each slide (at 
least 5 slides per mouse) contained 9–12 aortic root sections collected at 40 μ m intervals; with this scheme, con-
secutive, or immediately adjacent sections –which are morphologically and compositionally identical- are located 
in separate slides, allowing for different stainings to be conducted. Additional sections were collected at the end to 
be used as controls in immunostaining procedures. Lesion analysis, Oil Red O (ORO) and hematoxylin and eosin 
(H&E) stainings were as described in ref. 17. Areas of necrosis and cap thickness were evaluated as we describe in 
detail in ref. 17. With this protocol, cap thickness is assessed from the largest necrotic cores from at least duplicate 
sections and measuring the thinnest section of the cap as determined by the distance between the outer edge 
of the cap and the necrotic core border. Buried caps in deep necrosis areas, when present, were not considered 
for measurements. Collagen content was evaluated in sections stained with Movat’s pentachrome (American 
MasterTech, CA) following the manufacturer’s instructions. Staining for in situ TUNEL was performed using an 
in situ cell death detection kit (Roche, IN) as in refs 44,45, with the modifications described in ref. 17.
Immunohistochemistry. Immunohistochemistry (IHC) was performed using the Vecstatin Elite ABC kit 
(Vector Labs) and following the manufacturer’s instructions. Briefly, sections were fixed in acetone, endogenous 
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peroxidase quenched in 0.3% hydrogen peroxide in methanol, and processed for immunostaining for CD68 
(#MCA1957GA, Bio-Rad), inducible nitric oxide synthase (“iNOS”, antibody #ab15323, Abcam), mannose recep-
tor (“CD206”, antibody #ab64693, Abcam) or α -smooth muscle actin (“α SMA”, antibody #ab5294, Abcam). After 
treatment with secondary antibodies (for CD68: biotinylated goat anti-rat antibody #BA-9401, Vector laborato-
ries; for iNOS, CD206 and α SMA: biotinylated goat anti-rabbit antibody, Vecstatin Elite ABC kit, Vector laborato-
ries), sections were incubated with Vectastain ABC reagent and peroxidase substrate solution (# SK-4100, Vector 
laboratories). Counterstaining was with hematoxylin. Negative controls were performed by substituting the pri-
mary antibody with non-immune IgG from the same species and at the same concentration. Under these condi-
tions, nonspecific immunostaining was not detected. Stained areas were captured (Micropublisher 3.3 Megapixel 
Cooled CCD Color Digital Camera) and measured (NIS Elements D).
Immunostaining for M1 and M2 macrophages. This was performed as in ref. 17, with modifications. 
M1 and M2 macrophages in aortic root sections were identified by co-staining for iNOS (#ab15323, Abcam) or 
mannose receptor (“CD206”, #64693, Abcam), respectively, and macrophage (CD68, #MCA1957GA, Bio-Rad), 
as follows: frozen sections were fixed in acetone (15 min, 4 °C), non-specific sites blocked, and this was followed 
by simultaneous incubation with antibodies against iNOS (1:100 dilution) and CD68 (1:300 dilution), or CD206 
(1:100 dilution) and CD68 (1:300) for 3 hours. Sections were then incubated simultaneously with anti-rabbit 
IgG Alexa Fluor-555 (#4413 S, Cell Signaling) and anti-rat IgG Alexa Fluor-488 (#4416 S, Cell Signaling), both 
at 1:1,000 dilution (1 hour). Slides were mounted using the Prolong Gold Antifade Reagent with DAPI (Cell 
Signaling, #8961). All antibody dilutions were done using the IHC TEK antibody diluent (IW-1,000, IHC World).
In situ efferocytosis. Performed as described in refs 46,47, by simultaneously staining sections for 
TUNEL, CD68 and nuclei (DAPI). In situ efferocytosis was estimated by counting number of free vs. 
macrophage-associated apoptotic cells within plaques. “Free” apoptotic bodies were defined as TUNEL+ nuclei 
neither surrounded nor in contact with macrophages (CD68+ cells). TUNEL+ cells overlapping or in juxtapo-
sition to macrophages were considered “macrophage-associated”. “Free” vs. “macrophage-associated” apoptotic 
bodies were evaluated by 2 independent operators blinded to the samples (concurrence between the operators 
was > 90%).
Laser capture microdissection of plaque macrophages. iNOS+ or CD206+ cells within CD68+ immu-
noreactive areas in plaques from aortic root sections (6 μ M) were isolated by laser capture microdissection (LCM) 
essentially as described in ref. 48. Total RNA (3 pools of RNA per group, each from 2 mice) was prepared and used 
to measure the expression level of Trpc3, M1 markers (iNOS, Arg2, TNFα ) and M2 markers (Arg1, CD206, Ym1) 
by qRT-PCR. The primers used were described in refs 17,18. To estimate the enrichment in macrophage-derived 
RNA over whole-section RNA, we examined the expression levels of the macrophage-specific marker Cd68 and 
the smooth muscle cell marker α -smooth muscle actin (αSma) in LCM-captured iNOS+ and CD206+ cells. The 
LCM-derived RNA was markedly enriched (~30 fold) in mRNA for CD68 compared to whole-section RNA, 
whereas that of α -Sma was negligible; cyclophilin-A was used as control gene. LCM was performed on 6–8 aortic 
root sections per mouse using an Arcturus PixCell II LCM Instrument, following the protocol described in ref. 48. 
Approximately 300 laser pulses/section (15 μ m laser diameter, 40 mW power, 3 ms) were captured, RNA extracted 
(Arcturus Picopure RNA kit), amplified, purified and used for qRT-PCR.
Quantitative Real-time PCR (qRT-PCR). Was performed essentially as in ref. 18. Briefly, total RNA was 
prepared from bone marrow-derived macrophages using PerfectPure RNA Tissue kit (5Prime, MD) according 
to manufacturer’s instructions. cDNA was synthesized with oligo dT primers and reverse transcriptase (Applied 
Biosystems high capacity cDNA RT kit #4368814) using 1 μ g of total RNA. cDNA was used for semi-quantitative 
Real-time PCR (qRT-PCR) using TrueAmp SYBR green qPCR supermix (Applied Biosystems, CA). The relative 
amount of mRNA was normalized relative to glyceraldehyde 3-phosphate dehydrogenase (Gapdh). The primers 
used in qRT-PCR are described in ref. 18.
Statistical analysis. Values are shown as mean ± SEM and corresponding “n” numbers indicated in figure 
legends or text. Statistical differences were determined using the Student’s-t-Test with Prism Graph Pad version 
6 for Windows 2007 (Graph Pad Software, San Diego CA). P values of less than 0.05 were considered significant.
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Supplementary information 
REDUCED NECROSIS AND CONTENT OF APOPTOTIC M1 MACROPHAGES IN 
ADVANCED ATHEROSCLEROTIC PLAQUES OF MICE WITH MACROPHAGE-
SPECIFIC LOSS OF TRPC3   
Sumeet Solanki, Prabhatchandra R. Dube, Lutz Birnbaumer and Guillermo Vazquez 
 
Table S1.  
Body weight and lipid profile for Ldlr-/-Ldlr-/- and MacTrpc3-/-/Ldlr-/-Ldlr-/-
mice. Mice were fed a high fat diet for 14 weeks. Body weight and total plasma 
cholesterol and triglycerides were measured as described in Methods. Values are 
mean ± SEM, n= 11-12.
Ldlr-/-Ldlr-/- MacTrpc3-/-/Ldlr-/-Ldlr-/- 
Total cholesterol 
(mg/dl) 
1,012 ± 87 1,089 ± 91 
Triglycerides (mg/dl) 112 ± 20 123 ± 17 
Body weight before 
diet (g) 
Body weight after 
diet (g) 
16.21 ± 0.17 
21.39 ± 1.34 
16.48 ± 0.25 
18.98 ± 0.50 
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LEGENDS TO SUPPLEMENTAL FIGURES 
Supplemental Figure S1. 
Lethally irradiated female Ldlr-/- mice were transplanted with bone marrow from 
MacTrpc3-/-/Ldlr-/- (MacTrpc3-/-/Ldlr-/-Ldlr-/-, n=12) or Ldlr-/- mice (Ldlr-/-Ldlr-/-, n=12). 
The genotyping was performed using gDNA from peripheral blood (submandibular vein 
6 puncture) collected at four weeks after bone marrow transplantation to examine Trpc3 
by PCR. The 461 bp band corresponds to Trpc3 with floxed exon 7 (see 45), whereas 
the 380 bp band corresponds to wild-type Trpc3. 
 
Supplemental Figure S2. 
Quantitative real-time PCR on cDNA from BMDMs isolated from Ldlr-/-Ldlr-/- 
(Trpc3+/+BM) or MacTrpc3-/-/Ldlr-/-Ldlr-/- mice (Trpc3-/-BM) 14 weeks after bone marrow 
transplantation. Data is shown as mean ± SEM (n=3). The primers used for Trpc3 were 
described in 18. 
 
Supplemental Figure S3. 
Aortic root sections from Ldlr-/-Ldlr-/- or MacTrpc3-/-/Ldlr-/-Ldlr-/- mice that were 
maintained on a high fat diet for 14 weeks were stained with Oil-Red-O to evaluate 
neutral lipid content. The quantitation (mean ± SEM) of stained areas is shown. Ldlr-/-
Ldlr-/- (n=10), MacTrpc3-/-/Ldlr-/-Ldlr-/- (n=11). Total magnification: 50x. 
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Supplemental Figure S4. 
Aortic root sections from Ldlr-/-Ldlr-/- or MacTrpc3-/-/Ldlr-/-Ldlr-/- mice maintained on a 
14 week high fat diet were stained with A) Movat’s pentachrome to evaluate collagen 
content (yellow-to-yellow orange staining); or B) immunostained for α-smooth muscle 
actin (αSMA) and counterstained with H&E. In both “A” and “B” representative sections 
and the corresponding quantitations of mean stained areas (mean ± SD) for Ldlr-/-Ldlr-
/- (n=6-9) and MacTrpc3-/-/Ldlr-/-Ldlr-/- (n=6-8) are shown. Total magnification: 50x. 
 
Supplemental Figure S5. 
Aortic root sections from Ldlr-/-Ldlr-/- or MacTrpc3-/-/Ldlr-/-Ldlr-/- mice that were 
maintained on a high fat diet for 14 weeks were processed simultaneously for in situ 
TUNEL, to detect apoptotic cells (red), immunodetection of CD68 (macrophage marker, 
green) and nuclei staining (DAPI). Total magnification: 100x. Typical areas containing 
TUNEL+ and CD68+ cells (white dotted box in full image) are shown at higher 
magnification in the insets. Quantitations are shown in the bar graph (mean ± SEM, 
n=6). 
 
Supplemental Figure S6. 
Laser capture microdissection was applied to aortic root sections from Ldlr-/-Ldlr-/- or 
MacTrpc3-/-/Ldlr-/-Ldlr-/- mice that were kept on high fat diet for 14 weeks, to isolate 
iNOS+ or CD206+ cells that localized within CD68+ immunoreactive areas 
[iNOS+(CD68+) and CD206+(CD68+), respectively]. Total RNA (3 pools of RNA per 
group, each from 2 mice) was prepared and used to measure expression of Trpc3, M1 
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markers (iNOS, Arg2, TNFα) and M2 markers (Arg1, CD206, Ym1) by qRT-PCR. 
Differences between expression of M1 and M2 markers within the iNOS+(CD68+) group 
or within the CD206+(CD68+) group, and those between M1 or M2 markers in 
iNOS+(CD68+) vs. CD206+(CD68+), had all p values <0.0001. 
 
Supplemental Figure S7. 
Aortic root sections from Ldlr-/-Ldlr-/- or MacTrpc3-/-/Ldlr-/-Ldlr-/- mice that were 
maintained on a high fat diet for 14 weeks were processed simultaneously for in situ 
TUNEL (apoptotic cells, red), immunodetection of CD68 (macrophage marker, green) 
and nuclei staining (DAPI, blue). Total magnification: 400x. “Free” and “macrophage 
associated” (“Mϕ-associated”) apoptotic cells –see text for definitions- were counted to 
determine the ratio of free:Mϕ-associated apoptotic cells as an evaluation of in situ 
efferocytosis. The bar graph shows mean ± SD, n=6; ns: not statistically significant 
difference. 
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